Merck BPH therapy
Merck discontinues development of Synaptic's alpha adrenergic drug candidate for the oral treatment of benign prostatic hyperplasia. A Phase IIa trial found the drug, developed under a licensing deal covering alpha-1a antagonists, increased urine flow and showed less potential for cardiovascular side effects. Merck cited limited oral bioavailability and the potential for drug interactions in explaining its decision, Synaptic said. "The Synaptic technology has worked perfectly," Synaptic CEO Kathleen Mullen told a Bear Stearns conference in New York Sept. 15. "I'm not saying that Synaptic technology is great but big pharma fell down on the job"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth